Is I-123-beta-methyl-p-iodophenyl-methylpentadecanoic acid imaging useful to evaluate asymptomatic patients with hypertrophic cardiomyopathy? I-123 BMIPP imaging to evaluate asymptomatic hypertrophic cardiomyopathy

International Journal of Cardiovascular Imaging

Volumn 19, Issue 6, 2003, Pages 499-510

  Narita, Michihiro ^a   Kurihara, Tadashi ^a  

^a SUMITOMO HOSPITAL   (Japan)

Author keywords

Asymptomatic; Follow up; Hypertrophic cardiomyopathy; I 123 beta methyl p iodophenyl methylpentadecanoic acid

Indexed keywords

15 (4 IODOPHENYL) 3 METHYLPENTADECANOIC ACID I 123;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG UPTAKE; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TEST; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE PERFUSION; HEART VENTRICLE WALL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PREDICTION; PROGNOSIS; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM;

CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FATTY ACIDS; FEMALE; HUMANS; IODINE RADIOISOTOPES; IODOBENZENES; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC;

EID: 0348220480     PISSN: 01679899     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:CAIM.0000004262.48898.5d     Document Type: Article

References (30)

1. Maron BJ, Bonow RO, Cannon RO III, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. New Eng J Med 1987; 316: 844-852.
2. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995; 92: 1680-1692.
3. Spirito P, Seidman CE, McKenna W, Naron BJ. Clinical course and prognosis of hypertrophic-cardiomyopathy in an outpatient population. New Eng J Med 1997; 336: 775-785.
4. Wynne J, Braunwald E. The cardiomyopathies and myocarditides: Toxic, chemical, and physical damage to the heart. In: Braunwald E editor Heart Disease: A Textbook of Cardiovascular Medicine, 4th ed. Philadelphia: WB Saunders, 1992; 1394-1450.
5. Spirito P, Chiarella F, Carratino L, Berriso MZ, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic-cardiomyopathy in an outpatient population. New Eng J Med 1989; 320: 749-755.
6. Yutani C, Imakita M, Ishibashi-Ueda H, et al. Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. Am Heart J 1985; 109: 545-553.
7. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative study cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 123-129.
8. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
9. Bingisser R, Candinas R, Schneider J, Hess OM. Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy. Int J Cardiol 1994; 44: 225-233.
10. Knapp FF, Ambrose KR, Goodman MM. New radioiodinated methyl-branched fatty acids for cardiac study. Eur J Nucl Med 1986; 12: S39-S44.
11. Tamaki N, Kawamoto M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: Assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992; 33: 659-667.
12. Knapp FF, Franken P, Kropp J. Cardiac SPECT with iodine-123-labeled fatty acids: Evaluation of myocardial viability with BMIPP. J Nucl Med 1995; 36: 1022-1030.
13. Kurata C, Wawarahara K, Taguchi T, et al. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. J Nucl Med 1992; 33: 6-13.
14. Ohtsuki K, Sugihara H, Umamoto I, Nakamura T, Nakagawa T, Nakagawa M. Clinical evaluation of hypertrophic cardiomyopathy by myocardial scintigraphy using 123I-labeled 15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid(123I-BMIPP). Nucl Med Commun 1994; 15: 441-447.
15. Matuo S, Nakamura Y, Takahashi M, Mitunami K, Kinoshita M. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J 1998; 62: 167-172.
16. 123I)iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. Ann Nucl Med 1996; 10: 71-78.
17. Yoshida M, Nakamura Y, Fukuhara T, et al. Prognostic determinants of hypertrophic cardiomyopathy, the results of the Shiga Cardiomyopathy Study. Jpn Cir J 1995; 59: 745-753.
18. Shimizu M, Ino H, Okeie K, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal (123)I-15-(p-Iodophenyl)-3(R,S)-methylpentadecanoic acid myocardial scintigraphy. Cardiology 2000; 93: 43-49.
19. Saolo S, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. Am J Cardiol 1987; 59: 123-129.
20. Cecchi F, Olivotto I, Lazzeroni E, et al. Clinical course of hypertrophic cardiomyopathy in a non selected population. The Experience of the Italian Multicenter Cardiomyopathy Study. G Ital Cardiol 1997; 27: 1133-1143.
21. Berman DS, Kiat HS, Van Train KF, Germano G, Maddahi J, Friedman JD. Myocardial perfusion imaging with technetium-99m-sestamibi: Comparative analysis of available imaging protocols. J Nucl Med 1994; 35: 681-688.
22. Hoe J, Powers J, Iskandrian AE. Exercise-rest same-day SPECT sestambi imaging to detect coronary artery disease. J Nucl Med 1997; 38: 200-203.
23. Narita M, Kurihara T. Fatty acid metabolism in patients with idiopathic dilated cardiomyopathy: Characteristics and prognostic implications. J Cardiol 1995; 25: 223-231.
24. 123I-BMIPP imaging in patients with myocardial infarction. Kakuigaku 1997; 34: 177-187.
25. 123I-BMIPP). Kakuigaku 1991; 28: 681-690.
26. 123I-BMIPP) in relation to the concentration of substrate of energy. Kakuigaku 1995; 32: 579-586.
27. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendation regarding quantitation in M-mode echocardiography: Result of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
28. Groven-McKay M, Schwaiger M, Krivokapich J, Kerloff JK, Phelps ME, Scherbert HR. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1989; 13: 317-324.
29. Hina K, Kusachi S, Iwasaki K, et al. Progression of left ventricular enlargement in patients with hypertrophic cardiomyopathy: Incidence and prognostic value. Clin Cardiol 1993; 16: 403-407.
30. Ishiwata S, Nishiyama S, Nakanishi S, et al. Natural history of 82 patients with hypertrophic cardiomyopathy: Follow-up for oven ten years. J Cardiol 1991; 21: 61-73.